JP4568383B2 - 血管形成の促進方法 - Google Patents

血管形成の促進方法 Download PDF

Info

Publication number
JP4568383B2
JP4568383B2 JP50951597A JP50951597A JP4568383B2 JP 4568383 B2 JP4568383 B2 JP 4568383B2 JP 50951597 A JP50951597 A JP 50951597A JP 50951597 A JP50951597 A JP 50951597A JP 4568383 B2 JP4568383 B2 JP 4568383B2
Authority
JP
Japan
Prior art keywords
relaxin
vegf
pharmaceutical composition
cells
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP50951597A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11511174A (ja
Inventor
ウネモリ，イライネ
Original Assignee
コルセラ，インコーポレイティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コルセラ，インコーポレイティッド filed Critical コルセラ，インコーポレイティッド
Publication of JPH11511174A publication Critical patent/JPH11511174A/ja
Application granted granted Critical
Publication of JP4568383B2 publication Critical patent/JP4568383B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP50951597A 1995-08-15 1996-08-15 血管形成の促進方法 Expired - Lifetime JP4568383B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US235595P 1995-08-15 1995-08-15
US60/002,355 1995-08-15
PCT/US1996/013321 WO1997006814A1 (en) 1995-08-15 1996-08-15 Method of promoting angiogenesis

Publications (2)

Publication Number Publication Date
JPH11511174A JPH11511174A (ja) 1999-09-28
JP4568383B2 true JP4568383B2 (ja) 2010-10-27

Family

ID=21700396

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50951597A Expired - Lifetime JP4568383B2 (ja) 1995-08-15 1996-08-15 血管形成の促進方法

Country Status (9)

Country Link
US (3) US6211147B1 (de)
EP (1) EP0845992B1 (de)
JP (1) JP4568383B2 (de)
AT (1) ATE228004T1 (de)
AU (1) AU6777196A (de)
CA (1) CA2229479C (de)
DE (1) DE69624925T2 (de)
ES (1) ES2187667T3 (de)
WO (1) WO1997006814A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058468A1 (en) * 2000-02-09 2001-08-16 Connetics Corporation Use of relaxin to treat diseases related to vasoconstriction
ITRM20020119A1 (it) * 2002-03-05 2003-09-05 Geymonat Spa Composizioni contenenti plgf ad uso farmaceutico e cosmetico.
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
AU2005223694B2 (en) * 2004-03-19 2011-04-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
WO2005115435A2 (en) * 2004-04-30 2005-12-08 Bas Medical, Inc. Methods and compositions for control of fetal growth via modulation of relaxin
KR20080041145A (ko) * 2005-04-12 2008-05-09 인트라디그엠 코오포레이션 암 및 다른 신생혈관증식 질환을 치료하기 위한 ＲＮＡｉ치료제의 조성물 및 방법
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
US20060281669A1 (en) * 2005-06-13 2006-12-14 Yue Samuel K Method and compositions for the treatment of diabetes and related complications
US8496446B2 (en) * 2005-08-29 2013-07-30 Carrier Corporation Compressor muffler
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
MX2010012454A (es) * 2008-05-16 2011-03-29 Corthera Inc Star Metodo para promover la curacion de heridas.
US20110166070A1 (en) * 2008-05-16 2011-07-07 Stewart Dennis R Method of preventing premature delivery
EA201500552A1 (ru) 2008-05-16 2016-07-29 Кортера, Инк. Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью
BRPI0805852A8 (pt) * 2008-09-05 2021-06-29 Univ Rio De Janeiro polímeros ácidos protéicos, processos de produção, uso de polímeros ácidos protéicos, composição farmacêutica e método de tratamento
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
EP2334234A4 (de) 2008-09-19 2013-03-20 Tandem Diabetes Care Inc Vorrichtung zur messung der konzentration eines gelösten stoffs und entsprechende verfahren
US20110152770A1 (en) 2009-07-30 2011-06-23 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
SG10201506443TA (en) 2010-08-17 2015-10-29 Ambrx Inc Modified relaxin polypeptides and their uses
US10493131B2 (en) * 2011-08-31 2019-12-03 University Of Florida Research Foundation, Incorporated Materials and methods for modulating activity of bone marrow derived cells
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US9526762B1 (en) * 2013-08-09 2016-12-27 William Marsh Rice University Multidomain peptides for promoting angiogenesis
PT3387019T (pt) 2015-12-09 2022-01-14 Scripps Research Inst Proteínas de fusão de imunoglobulina de relaxina e métodos de uso

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023321A (en) 1982-12-13 1991-06-11 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a further gene sequence coding for human relaxin
US5023088A (en) * 1987-06-25 1991-06-11 Alza Corporation Multi-unit delivery system
ATE88352T1 (de) * 1988-02-26 1993-05-15 Genentech Inc Humanes relaxinpraeparat.
GB8907799D0 (en) * 1989-04-06 1989-05-17 Erba Carlo Spa Heteroaryl-3-oxo-propanenitrile derivatives useful in the treatment of rheumatoid arthritis and other autoimmune diseases
AU623518B2 (en) 1989-05-04 1992-05-14 Genentech Inc. Processes and compositions for the isolation of human relaxin
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5166191A (en) 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
US5478807A (en) 1991-08-19 1995-12-26 Genentech, Inc. Use of relaxin in the treatment of bradycardia
DE69434777T2 (de) * 1993-07-27 2007-06-14 Mario Bigazzi Verwendung von Relaxin zur Herstellung von therapeutischer Mittel
US5753623A (en) * 1995-06-07 1998-05-19 Connetics Corporation Method of treatment for depression
US5811395A (en) * 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
US5911997A (en) 1995-06-07 1999-06-15 Connetics Corporation Relaxin-like factor and methods and uses thereof

Also Published As

Publication number Publication date
AU6777196A (en) 1997-03-12
DE69624925D1 (de) 2003-01-02
ES2187667T3 (es) 2003-06-16
DE69624925T2 (de) 2003-09-04
WO1997006814A1 (en) 1997-02-27
US20040192606A1 (en) 2004-09-30
US20010018418A1 (en) 2001-08-30
EP0845992A1 (de) 1998-06-10
CA2229479C (en) 2010-03-30
US6211147B1 (en) 2001-04-03
EP0845992A4 (de) 2000-04-19
JPH11511174A (ja) 1999-09-28
ATE228004T1 (de) 2002-12-15
US6780836B2 (en) 2004-08-24
EP0845992B1 (de) 2002-11-20
CA2229479A1 (en) 1997-02-27

Similar Documents

Publication Publication Date Title
JP4568383B2 (ja) 血管形成の促進方法
KR101058467B1 (ko) 부신피질 자극 호르몬 유사체 및 관련 방법
Wilcox et al. Expression of acidic fibroblast growth factor mRNA in the developing and adult rat brain
Garcion et al. Expression of inducible nitric oxide synthase during rat brain inflammation: regulation by 1, 25‐dihydroxyvitamin D3
EP0309100B1 (de) Verwendung von Amylin oder CGRP zur Behandlung des Diabetes mellitus
Bitar Insulin and glucocorticoid-dependent suppression of the IGF-I system in diabetic wounds
US20020128294A1 (en) Nicotine in therapeutic angiogenesis and vasculogenesis
US6720340B1 (en) Nicotine receptor agonists in stem cell and progenitor cell recruitment
Clevenger et al. Interleukin-2 driven nuclear translocation of prolactin in cloned T-lymphocytes
WO2001058468A1 (en) Use of relaxin to treat diseases related to vasoconstriction
US9901619B2 (en) Compositions comprising PEDF and uses of same in the treatment and prevention of ovary-related syndromes
JP5400006B2 (ja) 虚血性疾患の予防または治療剤
JP2008507540A (ja) Ｐａｃａｐ化合物を用いる腎臓機能障害及び多発性骨髄腫の治療
WO2003057820A2 (en) Peptide activators of vegf
EP0855916B1 (de) Activin stimulator enthaltende pharmazeutische zusammensetzung
WO1999059614A1 (en) Modulation of angiogenesis and wound healing
US8361966B2 (en) Use of interleukin-11 as therapeutic agent for heart disease
JP2002517436A (ja) アデノシン二リン酸リボシルトランスフェラーゼの阻害を介する創傷処置
MXPA04002125A (es) Uso de la hl en la hiperestimulacion ovarica controlada.
WO1997018831A1 (fr) Protection des cellules endotheliales
WO1999043308A2 (en) Treating pulmonary hypertension through tenascin suppression and elastase inhibition
AU2003200309B2 (en) Pharmaceutical Composition for Preventing or Treating Ischaemic Diseases
Weiss et al. Synthesis and function of relaxin in human endometrium
US20030207811A1 (en) Method of treating retinopathy of prematurity using somatostatin analogs
JPH09143092A (ja) 心筋梗塞予防治療剤

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20061121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070905

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080130

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20080313

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20080319

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090529

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090804

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100614

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100809

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130813

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term